| Keywords: |
treatment response; acute granulocytic leukemia; leukemia, myeloid, acute; hydroxyurea; clinical trial; cancer recurrence; salvage therapy; monotherapy; cancer patient; cytarabine; methotrexate; drug megadose; neurotoxicity; nuclear magnetic resonance imaging; cancer diagnosis; cancer incidence; polymerase chain reaction; disease association; computer assisted tomography; multiple cycle treatment; etoposide; myeloperoxidase; maintenance therapy; combination chemotherapy; cytogenetics; nccn clinical practice guidelines; patient monitoring; practice guideline; hematopoietic stem cell transplantation; continuous infusion; acute lymphoblastic leukemia; arsenic trioxide; drug fatality; social support; cancer regression; blood sampling; mitoxantrone; practice guidelines as topic; daunorubicin; promyelocytic leukemia; cancer relapse; immunophenotyping; idarubicin; anthracycline; hla typing; retinoic acid; gemtuzumab ozogamicin; mercaptopurine; electrolyte balance; acute myeloid leukemia; chemotherapeutic agents; blood chemistry; leukemia treatment
|
